<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02706704</url>
  </required_header>
  <id_info>
    <org_study_id>OPH.RH.07</org_study_id>
    <nct_id>NCT02706704</nct_id>
  </id_info>
  <brief_title>Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis</brief_title>
  <acronym>IVAS</acronym>
  <official_title>Efficacy of Intravitreal Adalimumab Compared to Subcutaneous Adalimumab in Patients With Non-infectious Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American University of Beirut Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American University of Beirut Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare and evaluate the efficacy of subcutaneous (40mg)
      adalimumab biweekly injections to intravitreal adalimumab (1.5 mg/ 0.03 mL) administration,
      given at zero, 2 weeks then every four weeks, in subjects with active non-infectious
      intermediate-, posterior-, or pan-uveitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subject groups:

      32 subjects will be enrolled in this study, 16 in each arm. They will be randomized to
      receive either 1.5 mg/ 0.03 mL of adalimumab by intravitreal injection or 40 mg of adalimumab
      subcutaneously at their first treatment visit and at the 2 weeks visit if eligible for a
      repeat injection. Follow up will be every 2 days the first week then one week later and after
      that every 4-week intervals for total of 26 weeks.

      Intervention Details:

        -  Systemic adalimumab: Subcutaneous injection of 40 mg adalimumab (Humira) given every 2
           weeks.

        -  Local adalimumab: Intravitreal injection of 1.5mg/0.03ml adalimumab given at zero, 2
           weeks, and then every 4 weeks.

      Pre-treatment work up

      Patients will undergo a comprehensive eye exam:

        -  Visual acuity, slit-lamp examination of the anterior segment, dilated fundus
           examination, electroretinography (ERG) and fluorescein angiography (FA).

        -  Central macular thickness of all eyes will be measured with ocular coherence tomography
           before treatment.

        -  Purified Protein Derivative (PPD), Complete blood count (CBC) and SGPT.

      Post-injection follow-up

        -  Patients will be followed up every 2 days during the first week then one week later and
           after that every 4-week intervals.

        -  On follow up visits, if deterioration in vision of two or more ETDRS lines or worsening
           of ocular inflammation by more than 1+ cells/haze is detected at any visit, patients
           will be removed from the study and receive appropriate treatment. Otherwise, if vision
           was stable or improved and/or inflammation is same or better, patients will be
           re-injected.

        -  Follow up is for 26 weeks.

        -  OCT and fluorescein angiography each visit.

        -  ERG will be performed at baseline and 26 weeks.

        -  Blood studies (CBC and SGPT) will be performed at baseline, 14 weeks and at 26 weeks.

        -  Injections would be delayed if a patient has an acute infection and would be given when
           it subsides.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vitreous Haze</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Change in Vitreous Haze grade in each eye [National Eye Institute (NEI)/ Standardization of Uveitis Nomenclature (SUN) criteria]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anterior Chamber Cells</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Change in Anterior Chamber (AC) cell grade in each eye.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Change in ETDRS letters and logarithm of the minimum angle of resolution (log MAR) best-corrected visual acuity (BCVA) in each eye.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macular Edema</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Change in central retinal thickness on Optical Coherence Tomography (OCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiography Score</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Change in fluorescein angiography score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steroids Tapering</measure>
    <time_frame>26 Weeks</time_frame>
    <description>If the patient is initially on steroids (pre-enrolment); Success in tapering steroid dose as a response to the protocol.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Uveitis</condition>
  <condition>Non-Infectious Uveitis</condition>
  <arm_group>
    <arm_group_label>Intravitreal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal injection of 1.5mg/0.03ml adalimumab given at zero, 2 weeks, and then every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Systemic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous injection of 40 mg adalimumab (Humira) given every 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <arm_group_label>Intravitreal</arm_group_label>
    <arm_group_label>Systemic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is ≥ 18 years of age.

          -  Subject is diagnosed with non-infectious intermediate-, posterior-, or pan-uveitis.

          -  Subject must have active disease at baseline as defined by the presence of at least 1
             of the following parameters in at least one eye despite at least 2 weeks of prednisone
             ≥ 10 mg/day (or oral corticosteroid equivalent):

               -  Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion

               -  ≥ 1+ anterior chamber cells (Standardization of Uveitis Nomenclature [SUN]
                  criteria)

               -  ≥ 1+ vitreous haze (National Eye Institute [NEI]/SUN criteria)

          -  Subject with documented prior adequate response to oral corticosteroids (equivalent of
             oral prednisone up to 1 mg/kg/day).

          -  If subject is on prednisone &gt;=10 mg (or corticosteroid equivalent) at baseline, the
             dose has not been increased or decreased in the past 14 days.

          -  No increase in the immune modulatory therapy in the past three months

          -  Negative PPD test.

          -  Positive PPD test on anti Tb medications.

        Exclusion Criteria:

          -  Subject with isolated anterior uveitis.

          -  Subject with confirmed or suspected infectious uveitis, including but not limited to
             infectious uveitis due to TB, cytomegalovirus, lyme disease, toxoplasmosis and herpes
             simplex virus (HSV).

          -  Subject with serpiginous choroidopathy.

          -  Subject with corneal or lens opacity that precludes visualization of the fundus or
             that likely requires cataract surgery during the duration of the trial.

          -  Subject with corneal or lens opacities that preclude the evaluation of the vitreous
             haze.

          -  Subject with uncontrolled high intraocular pressure of ≥ 25 mmHg on maximal therapy.

          -  Subject with intermediate uveitis and symptoms and/or MRI findings suggestive of a
             demyelinating disease such as multiple sclerosis. All subjects with intermediate
             uveitis must have had a prior brain MRI at time of or after diagnosis of intermediate
             uveitis.

          -  Subject has received glucocorticosteroids implant (Retisert®), or Ozurdex within 6
             months prior to baseline visit.

          -  Subject has received intraocular or periocular corticosteroids or intravitreal
             methotrexate within 90 days prior to Baseline visit.

          -  Subject with proliferative or severe non-proliferative diabetic retinopathy.

          -  Subject with neovascular/wet age-related macular degeneration

          -  Subject with abnormality of vitreo-retinal interface (i.e., vitreomacular traction,
             epiretinal membranes, etc.) with the potential for macular structural damage
             independent of the inflammatory process.

          -  Subject with a systemic inflammatory disease and requires additional therapy with a
             systemic immunosuppressive agent at the time of study entry.

          -  Subjects with history of active or latent Mycobacterium tuberculosis documented by
             Purified Protein Derivative (PPD) and chest X-ray and not anti tuberculosis (TB)
             treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rola N Hamam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>American University of Beirut Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rola N Hamam, MD</last_name>
    <phone>+961-1-350000</phone>
    <phone_ext>5550</phone_ext>
    <email>rh46@aub.edu.lb</email>
  </overall_contact>
  <location>
    <facility>
      <name>American University of Beirut Medical Center</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rola N Hamam, MD</last_name>
      <phone>+961-1-350000</phone>
      <phone_ext>5550</phone_ext>
      <email>rh46@aub.edu.lb</email>
    </contact>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <reference>
    <citation>Hamam RN, Barikian AW, Antonios RS, Abdulaal MR, Alameddine RM, El Mollayess G, Mansour AM. Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study. Ocul Immunol Inflamm. 2016 Jun;24(3):319-26. doi: 10.3109/09273948.2014.990041. Epub 2014 Dec 30.</citation>
    <PMID>25549063</PMID>
  </reference>
  <reference>
    <citation>Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, Gómez Vidal MA, Collantes Estévez E, Ramírez Chamond R, Omar M. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001 Sep-Oct;33(5):251-5.</citation>
    <PMID>11586057</PMID>
  </reference>
  <reference>
    <citation>Pérez-Guijo V, Santos-Lacomba M, Sánchez-Hernández M, Castro-Villegas Mdel C, Gallardo-Galera JM, Collantes-Estévez E. Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin. 2004;20(2):155-7.</citation>
    <PMID>15006008</PMID>
  </reference>
  <reference>
    <citation>Rudwaleit M, Rødevand E, Holck P, Vanhoof J, Kron M, Kary S, Kupper H. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009 May;68(5):696-701. doi: 10.1136/ard.2008.092585. Epub 2008 Jul 28.</citation>
    <PMID>18662932</PMID>
  </reference>
  <reference>
    <citation>Mansour AM. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007 Mar;91(3):274-6.</citation>
    <PMID>17322463</PMID>
  </reference>
  <reference>
    <citation>Diaz-Llopis M, García-Delpech S, Salom D, Udaondo P, Hernández-Garfella M, Bosch-Morell F, Quijada A, Romero FJ. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther. 2008 Jun;24(3):351-61. doi: 10.1089/jop.2007.0104.</citation>
    <PMID>18476805</PMID>
  </reference>
  <reference>
    <citation>Wu L, Hernandez-Bogantes E, Roca JA, Arevalo JF, Barraza K, Lasave AF. intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group. Retina. 2011 Feb;31(2):298-303. doi: 10.1097/IAE.0b013e3181eac7a6.</citation>
    <PMID>21099452</PMID>
  </reference>
  <reference>
    <citation>Androudi S, Tsironi E, Kalogeropoulos C, Theodoridou A, Brazitikos P. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology. 2010 Aug;117(8):1612-6. doi: 10.1016/j.ophtha.2009.12.011. Epub 2010 Apr 8.</citation>
    <PMID>20378179</PMID>
  </reference>
  <reference>
    <citation>Manzano RP, Peyman GA, Carvounis PE, Damico FM, Aguiar RG, Ioshimoto GL, Ventura DF, Cursino ST, Takahashi W. Toxicity of high-dose intravitreal adalimumab (Humira) in the rabbit. J Ocul Pharmacol Ther. 2011 Aug;27(4):327-31. doi: 10.1089/jop.2010.0174. Epub 2011 Jun 13.</citation>
    <PMID>21668348</PMID>
  </reference>
  <reference>
    <citation>Tsilimbaris M, Diakonis VF, Naoumidi I, Charisis S, Kritikos I, Chatzithanasis G, Papadaki T, Plainis S. Evaluation of potential retinal toxicity of adalimumab (Humira). Graefes Arch Clin Exp Ophthalmol. 2009 Aug;247(8):1119-25. doi: 10.1007/s00417-009-1065-y. Epub 2009 Mar 19.</citation>
    <PMID>19296122</PMID>
  </reference>
  <reference>
    <citation>Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509-16. Review.</citation>
    <PMID>16196117</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2016</study_first_submitted>
  <study_first_submitted_qc>March 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2016</study_first_posted>
  <last_update_submitted>March 14, 2016</last_update_submitted>
  <last_update_submitted_qc>March 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intravitreal Adalimumab</keyword>
  <keyword>Subcutaneous Adalimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

